Potential of Dietary Agent Daidzein in Cancer Prevention and Treatment: Opportunities and Challenges
Cancers · 19.05.2026 · 18 (10) · 1639
DOI: 10.3390/cancers18101639 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.05.2026. Verfasst von Subhadas Chatterjee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Bengal School of Technology, Chuchura 712 102, West Bengal, India. Die Arbeit nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Daidzein, a secondary metabolite primarily obtained from soybean (Glycine max L.) and other legumes, has significant nutritional and pharmacological value. Chemically, daidzein is an isoflavone and plays a crucial role in the therapeutic amelioration of numerous disorders, including allergies, inflammation, diabetes, cardiovascular, and neurodegenerative diseases. Emerging preclinical evidence suggests potential antineoplastic activity of daidzein against various cancers. This current work aims to perform a critical evaluation of daidzein’s potential as an anticancer molecule with an in-depth understanding of its mechanisms of action.
Methods
The data for this review were obtained from various sources, including PubMed, Scopus, and Web of Science.
Results
Daidzein, as a pure phytochemical or in combination with other phytochemicals and anticancer drugs, has been reported to induce apoptotic and autophagic cell death, impeding cell growth, viability, proliferation, and angiogenesis, and arresting cell division at various phases in vitro. Various daidzein formulations also exhibited similar anticancer effects by immunomodulation and genetic alteration in the cancer cells. In vivo anticancer studies of daidzein also suggest modulation of several hallmark pathways, such as inhibition of nuclear factor-κB, Janus kinase/signal transducer and activator of transcription, and rat sarcoma virus/rapidly accelerated fibrosarcoma.
Conclusions
Irrespective of numerous promising preclinical studies, the absence of clinical studies provides a major challenge to establishing daidzein’s safety and efficacy in human cancers. Therefore, further advancements in clinical research of daidzein are vital for manifesting as an antineoplastic drug.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Bengal School of Technology, Chuchura 712 102, West Bengal, India.
- Department of Pharmaceutical Chemistry, Gupta College of Technological Sciences, Asansol 713 301, West Bengal, India.
- School of Pharmacy, The Neotia University, Sarisa 743 368, West Bengal, India.
- School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 999077, China.
- Department of Pharmacology, College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA.
ORCID-Profile: Sabyasachi Banerjee, Kumar Ganesan, Anupam Bishayee
Zitieren
APA
Chatterjee, S., Banerjee, S., Bose, S., Ganesan, K., Reilly, C. R., & Bishayee, A. (2026). Potential of Dietary Agent Daidzein in Cancer Prevention and Treatment: Opportunities and Challenges. Cancers, 18(10), 1639. https://doi.org/10.3390/cancers18101639
Vancouver
Chatterjee S, Banerjee S, Bose S, Ganesan K, Reilly CR, Bishayee A. Potential of Dietary Agent Daidzein in Cancer Prevention and Treatment: Opportunities and Challenges. Cancers. 2026;18(10):1639. doi:10.3390/cancers18101639
BibTeX
@article{Chatterjee2026,
author = {Chatterjee, Subhadas and Banerjee, Sabyasachi and Bose, Sankhadip and Ganesan, Kumar and Reilly, Cassandra R and Bishayee, Anupam},
title = {Potential of Dietary Agent Daidzein in Cancer Prevention and Treatment: Opportunities and Challenges},
journal = {Cancers},
year = {2026},
volume = {18},
number = {10},
pages = {1639},
doi = {10.3390/cancers18101639}
}
EUVIMED